J-F Colombel

List of Publications by Year
in descending order

447 papers	58,560 citations	2311 98 h-index	1109 231 g-index
457 all docs	457 docs citations	457 times ranked	29623 citing authors

#	Article	IF	Citations
1	Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature, 2001, 411, 599-603.	13.7	5,088
2	Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology & Hepatology, 2005, 19, 5A-36A.	1.8	2,711
3	The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut, 2006, 55, 749-753.	6.1	2,362
4	Ulcerative colitis. Lancet, The, 2017, 389, 1756-1770.	6.3	2,150
5	Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 2013, 369, 699-710.	13.9	2,114
6	Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine, 2013, 369, 711-721.	13.9	2,001
7	Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohnâ€™s Disease: The CHARM Trial. Gastroenterology, 2007, 132, 52-65.	0.6	1,986
8	Crohn's disease. Lancet, The, 2017, 389, 1741-1755.	6.3	1,594
9	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology, 2015, 110, 1324-1338.	0.2	1,425
10	Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointestinal Endoscopy, 2004, 60, 505-512.	0.5	1,326
11	High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohnâ€™s disease. Gastroenterology, 2004, 127, 412-421.	0.6	1,325
12	Ustekinumab as Induction and Maintenance Therapy for Crohnâ€™s Disease. New England Journal of Medicine, 2016, 375, 1946-1960.	13.9	1,316
13	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. Journal of Crohn's and Colitis, 2012, 6, 991-1030.	0.6	1,106
14	Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology, 2012, 142, 257-265.e3.	0.6	1,062
15	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology, 2021, 160, 1570-1583.	0.6	1,054
16	Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease. Gastroenterology, 2008, 134, 929-936.	0.6	913
17	Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. Annals of Internal Medicine, 2007, 146, 829.	2.0	849
18	Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, 443-468.	0.6	804

#	Article	IF	Citations
19	Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology, 2014, 146, 85-95.	0.6	753
20	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet, The, 2017, 390, 2779-2789.	6.3	633
21	The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut, 2017, 66, 839-851.	6.1	630
22	Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology, 2020, 159, 481-491.e3.	0.6	613
23	Effects of Vedolizumab Induction Therapy for Patients With Crohnâ€™s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. Gastroenterology, 2014, 147, 618-627.e3.	0.6	607
24	Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology, 2014, 146, 96-109.e1.	0.6	605
25	Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial. Gastroenterology, 2012, 142, 1102-1111.e2.	0.6	485
26	Geographical variability and environmental risk factors in inflammatory bowel disease. Gut, 2013, 62, 630-649.	6.1	476
27	Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clinical and Translational Gastroenterology, 2016, 7, e135.	1.3	473
28	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. New England Journal of Medicine, 2019, 381, 1215-1226.	13.9	457
29	Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease. Gastroenterology, 2011, 141, 1621-1628.e5.	0.6	431
30	Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut, 2018, 67, 574-587.	6.1	366
31	Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORÎ³t+ Regulatory T Cells and Exacerbate Colitis in Mice. Immunity, 2019, 50, 212-224.e4.	6.6	345
32	Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohnâ€™s Disease. MBio, 2016, 7, .	1.8	335
33	Antibiotics Associated With Increased Risk of New-Onset Crohnâ€™s Disease But Not Ulcerative Colitis: A Meta-Analysis. American Journal of Gastroenterology, 2014, 109, 1728-1738.	0.2	292
34	Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut, 2012, 61, 241-247.	6.1	291
35	Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. Gastroenterology, 2019, 156, 1440-1454.e2.	0.6	290
36	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut, 2017, 66, 1049-1059.	6.1	274

#	Article	IF	Citations
37	The Natural History of Pediatric Ulcerative Colitis: A Population-Based Cohort Study. American Journal of Gastroenterology, 2009, 104, 2080-2088.	0.2	273
38	Interactions Between Diet and the Intestinal Microbiota Alter Intestinal Permeability and Colitis Severity in Mice. Gastroenterology, 2018, 154, 1037-1046.e2.	0.6	273
39	Systematic review with metaâ€analysis: mucosal healing is associated with improved longâ€term outcomes in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 317-333.	1.9	264
40	The Real-World Effectiveness and Safety of Vedolizumab for Moderateâ€“Severe Crohnâ€™s Disease: Results From the US VICTORY Consortium. American Journal of Gastroenterology, 2016, 111, 1147-1155.	0.2	257
41	Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2016, 14, 1245-1255.e8.	2.4	255
42	Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut, 2003, 52, 552-557.	6.1	251
43	Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut, 2021, 70, 725-732.	6.1	240
44	Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology, 2017, 152, 351-361.e5.	0.6	220
45	Ulcerative Colitis as A Progressive Disease: The Forgotten Evidence. Inflammatory Bowel Diseases, 2012, 18, 1356-1363.	0.9	207
46	Adalimumab Induces Deep Remission in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 414-422.e5.	2.4	204
47	Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut, 2005, 54, 357-363.	6.1	203
48	Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data. American Journal of Gastroenterology, 2010, 105, 1574-1582.	0.2	201
49	A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2012, 107, 1051-1063.	0.2	194
50	Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohnâ€™s Disease. Gastroenterology, 2020, 158, 2123-2138.e8.	0.6	189
51	Urbanization and the gut microbiota in health and inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 440-452.	8.2	187
52	Converging Goals of Treatment of Inflammatory Bowel Disease From Clinical Trials and Practice. Gastroenterology, 2015, 148, 37-51.e1.	0.6	185
53	Management of Patients With Crohnâ€™s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology, 2020, 159, 6-13.e6.	0.6	185
54	IBD across the age spectrumâ€”is it the same disease?. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 88-98.	8.2	183

#	Article	IF	Citations
55	Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology, 2015, 149, 1716-1730.	0.6	180
56	Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. Journal of Crohn's and Colitis, 2020, 14, 254-266.	0.6	175
57	Systematic Review and Meta-analysis. Inflammatory Bowel Diseases, 2017, 23, 1702-1709.	0.9	174
58	Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease. Gastroenterology, 2014, 146, 941-949.e2.	0.6	172
59	A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. American Journal of Gastroenterology, 2019, 114, 874-883.	0.2	167
60	Randomised clinical trial: deep remission in biologic and immunomodulator naÃ¯ve patients with Crohn's disease â€“ a <scp>SONIC </scp>post hoc analysis. Alimentary Pharmacology and Therapeutics, 2015, 41, 734-746.	1.9	158
61	Mycobiota in gastrointestinal diseases. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 77-87.	8.2	157
62	Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC. Gastroenterology, 2013, 145, 978-986.e5.	0.6	155
63	Sex-Based Differences in Incidence of Inflammatory Bowel Diseasesâ€”Pooled Analysis of Population-Based Studies From Western Countries. Gastroenterology, 2018, 155, 1079-1089.e3.	0.6	155
64	Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease. Journal of Crohn's and Colitis, 2013, 7, 213-221.	0.6	152
65	Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. American Journal of Gastroenterology, 2016, 111, 477-491.	0.2	151
66	IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2020, 14, 23-32.	0.6	149
67	Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies. Journal of Crohn's and Colitis, 2014, 8, 469-479.	0.6	145
68	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohnâ€™s Disease. Gastroenterology, 2019, 157, 1007-1018.e7.	0.6	145
69	Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Annals of the Rheumatic Diseases, 2019, 78, 473-479.	0.5	143
70	Long-term Efficacy of Vedolizumab for Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2017, 11, jjw176.	0.6	141
71	Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3. American Journal of Gastroenterology, 2014, 109, 1771-1780.	0.2	140
72	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, jjw177.	0.6	140

#	Article	IF	Citations
73	Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease. JAMA - Journal of the American Medical Association, 2015, 314, 2524.	3.8	136
74	The intestinal barrier, an arbitrator turned provocateur in IBD. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 83-84.	8.2	134
75	Exposureâ€“efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2017, 11, 921-929.	0.6	130
76	Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology, 2020, 159, 96-104.	0.6	129
77	Longâ€term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Alimentary Pharmacology and Therapeutics, 2018, 48, 65-77.	1.9	128
78	Inflammatory Bowel Disease and the Elderly: A Review. Journal of Crohn's and Colitis, 2015, 9, 507-515.	0.6	127
79	Deep Remission at 1 Year Prevents Progression of Early Crohnâ€™s Disease. Gastroenterology, 2020, 159, 139-147.	0.6	126
80	Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohnâ€™s Disease. Gastroenterology, 2018, 155, 1045-1058.	0.6	125
81	Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 1525-1532.e1.	2.4	124
82	The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1896-1905.	0.9	124
83	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut, 2014, 63, 1416-1423.	6.1	122
84	Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice. Gut, 2020, 69, 42-51.	6.1	121
85	Cancer Recurrence Following Immune-Suppressive Therapies inÂPatients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology, 2016, 151, 97-109.e4.	0.6	120
86	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology, 2018, 113, 1345.	0.2	119
87	Gut microbiota density influences host physiology and is shaped by host and microbial factors. ELife, 2019, 8, .	2.8	118
88	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology, 2021, 160, 2435-2450.e34.	0.6	118
89	Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 423-431.e1.	2.4	117
90	Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut, 2017, 66, 588-596.	6.1	117

#	Article	IF	Citations
91	Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2016, 10, 1385-1394.	0.6	115
92	The features of mucosaâ€associated microbiota in primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2016, 43, 790-801.	1.9	112
93	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Alimentary Pharmacology and Therapeutics, 2016, 43, 252-261.	1.9	111
94	Adalimumab safety in global clinical trials of patients with CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2009, 15, 1308-1319.	0.9	110
95	Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2012, 18, 349-358.	0.9	110
96	Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. Cell Host and Microbe, 2020, 27, 823-829.e3.	5.1	110
97	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Antiâ€“Tumor Necrosis Factor Therapy for Crohnâ€™s Disease: A Meta-analysis of Placebo-controlled Trials. Clinical Gastroenterology and Hepatology, 2015, 13, 2233-2240.e2.	2.4	109
98	Development of an index to define overall disease severity in IBD. Gut, 2018, 67, 244-254.	6.1	108
99	Systematic review: monotherapy with antitumour necrosis factor Î± agents versus combination therapy with an immunosuppressive for IBD. Gut, 2014, 63, 1843-1853.	6.1	106
100	Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery. Gut, 2016, 65, 954-962.	6.1	106
101	Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Alimentary Pharmacology and Therapeutics, 2017, 45, 801-813.	1.9	106
102	Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis. Alimentary Pharmacology and Therapeutics, 2016, 43, 1300-1310.	1.9	105
103	Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut, 2017, 66, 2063-2068.	6.1	104
104	Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an openâ€label, prospective and randomised clinical trial. Alimentary Pharmacology and Therapeutics, 2017, 46, 142-149.	1.9	104
105	AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Clinical Gastroenterology and Hepatology, 2019, 17, 380-390.e1.	2.4	104
106	Biologics in inflammatory bowel disease: what are the data?. United European Gastroenterology Journal, 2015, 3, 419-428.	1.6	102
107	Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology, 2021, 161, 715-718.e4.	0.6	102
108	Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 896-905.	1.9	99

#	Article	IF	Citations
109	Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2â€“related Disease. Gastroenterology, 2021, 160, 287-301.e20.	0.6	98
110	Adalimumab maintains remission of Crohn's disease after up to 4Âyears of treatment: data from <scp>CHARM</scp> and <scp>ADHERE</scp>. Alimentary Pharmacology and Therapeutics, 2013, 38, 1236-1247.	1.9	97
111	Longâ€term safety of vedolizumab for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1353-1365.	1.9	97
112	Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases. Gastroenterology, 2020, 158, 95-110.	0.6	95
113	Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohnâ€™s Disease: The IM-UNITI Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 578-590.e4.	2.4	94
114	Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Clinical Gastroenterology and Hepatology, 2016, 14, 58-64.	2.4	93
115	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohnâ€™sÂDisease. Gastroenterology, 2018, 155, 687-695.e10.	0.6	93
116	Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders. Clinical Gastroenterology and Hepatology, 2018, 16, 1374-1384.	2.4	91
117	Systematic review: safety of mesalazine in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2018, 47, 1597-1609.	1.9	90
118	Adalimumab sustains clinical remission and overall clinical benefit after 2â€ƒyears of therapy for Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2010, 31, 1296-1309.	1.9	88
119	Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. Journal of the American Academy of Dermatology, 2017, 76, 441-448.e2.	0.6	86
120	Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Userâ€™s Guide for Adult and Pediatric Gastroenterologists. Gastroenterology, 2021, 161, 47-65.	0.6	86
121	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open, 2021, 4, e2129639.	2.8	86
122	Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. Journal of Crohn's and Colitis, 2013, 7, 950-957.	0.6	83
123	Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention. Inflammatory Bowel Diseases, 2018, 24, 2173-2182.	0.9	83
124	The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. United European Gastroenterology Journal, 2018, 6, 112-122.	1.6	81
125	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 892-899.e2.	2.4	80
126	The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunology, 2018, 11, 1558-1570.	2.7	80

#	Article	IF	Citations
127	Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 130-138.e7.	2.4	76
128	High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 1106-1113.e3.	2.4	74
129	Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut, 2015, 64, 438-446.	6.1	72
130	Factors Associated With Short- and Long-Term Outcomes ofÂTherapy for Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 539-547.e2.	2.4	71
131	Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 538-545.	0.6	71
132	Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohnâ€™s Disease in Sustained Remission. Clinical Gastroenterology and Hepatology, 2018, 16, 234-243.e2.	2.4	71
133	Inflammatory Bowel Disease 2017: Innovations and Changing Paradigms. Gastroenterology, 2017, 152, 309-312.	0.6	69
134	Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1592-1601.e3.	2.4	69
135	Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut, 2016, 65, 1061-1069.	6.1	68
136	Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. Journal of Crohn's and Colitis, 2018, 12, 610-620.	0.6	67
137	Randomised clinical study: discrepancies between patientâ€reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2015, 42, 1082-1092.	1.9	66
138	Improving quality of care in inflammatory bowel disease: What changes can be made today?. Journal of Crohn's and Colitis, 2014, 8, 919-926.	0.6	65
139	Anti-Î±4Î²7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1â€“infected individuals. Science Translational Medicine, 2018, 10, .	5.8	65
140	Efficacy and safety of tofacitinib dose deâ€escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Alimentary Pharmacology and Therapeutics, 2020, 51, 271-280.	1.9	65
141	Identifying strains that contribute to complex diseases through the study of microbial inheritance. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 633-640.	3.3	63
142	Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. Journal of Crohn's and Colitis, 2019, 13, 50-57.	0.6	61
143	Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. Journal of Crohn's and Colitis, 2016, 10, 418-428.	0.6	60
144	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1533-1540.e2.	2.4	60

#	Article	IF	Citations
145	Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes. Nature Microbiology, 2021, 6, 1309-1318.	5.9	60
146	Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohnâ€™s Disease. Gastroenterology, 2018, 154, 61-64.e6.	0.6	59
147	No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases. Gastroenterology, 2019, 156, 1333-1344.e3.	0.6	58
148	Defined microbiota transplant restores Th17/RORÎ³t⁺regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21536-21545.	3.3	58
149	Systematic review and metaâ€analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 831-842.	1.9	58
150	Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial. JMIR Research Protocols, 2015, 4, e23.	0.5	58
151	Crohnâ€™s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. American Journal of Gastroenterology, 2016, 111, 1806-1815.	0.2	57
152	De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2020, 5, 63-79.	3.7	56
153	Review article: nonâ€malignant oral manifestations in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2015, 42, 40-60.	1.9	55
154	Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease. American Journal of Gastroenterology, 2016, 111, 1416-1423.	0.2	55
155	Systematic review with metaâ€analysis: proximal disease extension in limited ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2017, 45, 1481-1492.	1.9	55
156	What Should Gastroenterologists and Patients Know About COVID-19?. Clinical Gastroenterology and Hepatology, 2020, 18, 1409-1411.	2.4	54
157	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. New England Journal of Medicine, 2016, 375, 2101-2102.	13.9	53
158	Role of mannose-binding lectin in intestinal homeostasis and fungal elimination. Mucosal Immunology, 2016, 9, 767-776.	2.7	53
159	PPAR-Gamma in Ulcerative Colitis: A Novel Target for Intervention. Current Drug Targets, 2013, 14, 1501-1507.	1.0	52
160	Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohnâ€™s Disease Treated With Infliximab [Remicade^{Â®}] or Conventional Therapy. Journal of Crohn's and Colitis, 2017, 11, jjw221.	0.6	51
161	Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitisâ€”A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 2185-2198.e3.	2.4	51
162	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2461-2467.	0.9	50

#	Article	IF	Citations
163	Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver Agreement. PLoS ONE, 2015, 10, e0120299.	1.1	49
164	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. The Lancet Gastroenterology and Hepatology, 2022, 7, 118-127.	3.7	49
165	Multiomics to elucidate inflammatory bowel disease risk factors and pathways. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 399-409.	8.2	49
166	Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?. Expert Review of Gastroenterology and Hepatology, 2015, 9, 781-795.	1.4	48
167	Incidence, Clinical Presentation, and Associated Factors of Microscopic Colitis in Northern France: A Population-Based Study. Digestive Diseases and Sciences, 2017, 62, 1571-1579.	1.1	48
168	Sexâ€based differences in the incidence of inflammatory bowel diseasesâ€”pooled analysis of populationâ€based studies from the Asiaâ€Pacific region. Alimentary Pharmacology and Therapeutics, 2019, 49, 904-911.	1.9	48
169	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 669-681.	1.9	48
170	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2952-2961.e8.	2.4	48
171	Intestinal steroidogenesis controls PPARÎ³ expression in the colon and is impaired during ulcerative colitis. Gut, 2015, 64, 901-910.	6.1	47
172	Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Alimentary Pharmacology and Therapeutics, 2017, 45, 50-62.	1.9	47
173	Early life exposures and the risk of inflammatory bowel disease: Systematic review and meta-analyses. EClinicalMedicine, 2021, 36, 100884.	3.2	47
174	Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry. Inflammatory Bowel Diseases, 2021, 27, 585-589.	0.9	47
175	High-Dose Infliximab Therapy in Crohnâ€™s Disease: Clinical Experience, Safety, and Efficacy. Journal of Crohn's and Colitis, 2015, 9, 266-275.	0.6	46
176	Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry. Gastroenterology, 2022, 162, 316-319.e5.	0.6	46
177	Magnetic Resonance Imaging Predicts Histopathological Composition of Ileal Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2018, 12, 718-729.	0.6	45
178	Challenges in IBD Research: Preclinical Human IBD Mechanisms. Inflammatory Bowel Diseases, 2019, 25, S5-S12.	0.9	44
179	Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. The Lancet Gastroenterology and Hepatology, 2019, 4, 287-295.	3.7	44
180	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohnâ€™s Disease But Not Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2497-2505.e1.	2.4	44

#	Article	IF	Citations
181	The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils. Mucosal Immunology, 2016, 9, 322-335.	2.7	43
182	O-001â€ƒA Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service CrohnÊ¼s Disease Refractory to Anti-TFNÎ±. Inflammatory Bowel Diseases, 2016, 22, S1.	0.9	42
183	Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis. Gut, 2019, 68, 2152-2160.	6.1	42
184	JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications. Journal of Crohn's and Colitis, 2020, 14, S755-S760.	0.6	42
185	A characterization of pro-inflammatory cytokines in dextran sulfate sodium-induced chronic relapsing colitis mice model. International Immunopharmacology, 2018, 60, 194-201.	1.7	41
186	Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut, 2019, 68, 977-984.	6.1	41
187	Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their Babies. Gastroenterology, 2021, 160, 1118-1130.e3.	0.6	41
188	Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. Gastroenterology, 2016, 150, 389-395.e3.	0.6	40
189	Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 411-418.e3.	2.4	40
190	Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases. Clinical Gastroenterology and Hepatology, 2021, 19, 394-396.e5.	2.4	40
191	Adalimumab sustains steroidâ€free remission after 3â€ƒyears of therapy for Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 306-317.	1.9	39
192	Effects of vedolizumab on healthâ€related quality of life in patients with ulcerative colitis: results from the randomised <scp>GEMINI</scp> 1 trial. Alimentary Pharmacology and Therapeutics, 2017, 45, 264-275.	1.9	39
193	Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?. Gastrointestinal Endoscopy Clinics of North America, 2019, 29, 421-436.	0.6	39
194	Increasing Prevalence of Frailty and Its Association with Readmission and Mortality Among Hospitalized Patients with IBD. Digestive Diseases and Sciences, 2021, 66, 4178-4190.	1.1	38
195	Higher vs Standard Adalimumab Induction Dosing Regimens andÂTwo Maintenance Strategies: Randomized SERENE CD TrialÂResults. Gastroenterology, 2022, 162, 1876-1890.	0.6	37
196	Anal Neoplasia in Inflammatory Bowel Disease Is Associated With HPV and Perianal Disease. Clinical and Translational Gastroenterology, 2016, 7, e148.	1.3	36
197	Aging and IBD: A New Challenge for Clinicians and Researchers. Inflammatory Bowel Diseases, 2022, 28, 126-132.	0.9	36
198	Genetics and phenotypes in inflammatory bowel disease. Lancet, The, 2016, 387, 98-100.	6.3	35

#	Article	IF	Citations
199	Features of Patients With Crohnâ€™s Disease and HidradenitisÂSuppurativa. Clinical Gastroenterology and Hepatology, 2016, 14, 71-79.	2.4	35
200	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 533-541.	1.9	35
201	Longâ€term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2018, 47, 219-228.	1.9	35
202	Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasisâ€"A Nationwide 20-Year Cohort Study. Journal of Investigative Dermatology, 2019, 139, 316-323.	0.3	35
203	Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort. Journal of Crohn's and Colitis, 2017, 11, 1200-1204.	0.6	34
204	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohnâ€™s Disease. Gastroenterology, 2018, 155, 76-87.	0.6	34
205	The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1101-1108.	1.4	34
206	Targeting B cells for inflammatory bowel disease treatment: back to the future. Current Opinion in Pharmacology, 2020, 55, 90-98.	1.7	34
207	Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Digestive and Liver Disease, 2015, 47, 356-364.	0.4	33
208	Systematic review: gastrointestinal infection and incident inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 1222-1232.	1.9	33
209	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBDâ€"Prediction and Prevention of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 1443-1454.	0.6	33
210	B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2016, 61, 3407-3424.	1.1	32
211	Diet Modifies Colonic Microbiota and CD4+ T-Cell Repertoire to Induce Flares of Colitis in Mice With Myeloid-Cell Expression of Interleukin 23. Gastroenterology, 2018, 155, 1177-1191.e16.	0.6	32
212	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 126-135.	2.4	32
213	Oral Cancer and Oral Precancerous Lesions in Inflammatory Bowel Diseases: A Systematic Review. Journal of Crohn's and Colitis, 2015, 9, 1043-1052.	0.6	31
214	Eldelumab [anti-interferon-Î³-inducible protein-10 antibody] Induction Therapy for Active Crohnâ€™s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. Journal of Crohn's and Colitis, 2017, 11, 811-819.	0.6	31
215	The Management of Intestinal Penetrating Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2018, 24, 752-765.	0.9	31
216	Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. The Cochrane Library, 2018, 5, CD012540.	1.5	31

#	Article	IF	Citations
217	Changing epidemiology of immune-mediated inflammatory diseases in immigrants: A systematic review of population-based studies. Journal of Autoimmunity, 2019, 105, 102303.	3.0	31
218	Review article: bacteriophages in gastroenterologyâ€"from biology to clinical applications. Alimentary Pharmacology and Therapeutics, 2020, 51, 53-63.	1.9	31
219	Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. The Lancet Gastroenterology and Hepatology, 2022, 7, 666-678.	3.7	31
220	Systematic review with metaâ€analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 121-131.	1.9	30
221	A clinical decision support tool may help to optimise vedolizumab therapy in Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 553-564.	1.9	30
222	The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110044.	1.4	28
223	SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges. Journal of Crohn's and Colitis, 2021, 15, 1376-1386.	0.6	28
224	Validation and Update of the LÃ©mann Index to Measure Cumulative Structural Bowel Damage in Crohnâ€™s Disease. Gastroenterology, 2021, 161, 853-864.e13.	0.6	28
225	Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. Crohn's & Colitis 360, 2022, 4, otac002.	0.5	28
226	Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study. Gut, 2019, 68, 615-622.	6.1	27
227	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohnâ€™s Disease: A Post Hoc Analysis From the CALM Study. Inflammatory Bowel Diseases, 2020, 26, 1562-1571.	0.9	27
228	Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease. Gastroenterology, 2021, 161, 394-399.	0.6	27
229	Increased Risk of Oral Cancer in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2016, 14, 413-420.	2.4	26
230	Bariatric surgery is associated with increased risk of newâ€onset inflammatory bowel disease: case series and national database study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1126-1134.	1.9	26
231	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. Clinical Gastroenterology and Hepatology, 2019, 17, 1673-1679.e1.	2.4	26
232	Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing Surveillance. Clinical Gastroenterology and Hepatology, 2020, 18, 1518-1527.e3.	2.4	26
233	Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohnâ€™s Disease: A Pilot Study (ACROHNEM). Journal of Clinical Medicine, 2020, 9, 41.	1.0	26
234	Integrative Analysis of the Inflammatory Bowel Disease Serum Metabolome Improves Our Understanding of Genetic Etiology and Points to Novel Putative Therapeutic Targets. Gastroenterology, 2022, 162, 828-843.e11.	0.6	26

#	Article	IF	Citations
235	Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 966-972.e2.	2.4	25
236	Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy, 2016, 83, 188-197.e3.	0.5	25
237	Treating Inflammatory Bowel Disease With Diet: A Taste Test. Gastroenterology, 2019, 157, 295-297.	0.6	25
238	Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohnâ€™s Disease Studies. Journal of Crohn's and Colitis, 2019, 13, 725-734.	0.6	25
239	Autoimmune and Chronic Inflammatory Disease Patients with COVIDâ€19. ACR Open Rheumatology, 2021, 3, 111-115.	0.9	25
240	Cohort profile of the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS) study: Rationale, organization, design, and baseline characteristics. Contemporary Clinical Trials Communications, 2019, 14, 100345.	0.5	24
241	Viewpoint: Inflammatory Bowel Diseases Among Immigrants From Low- to High-Incidence Countries: Opportunities and Considerations. Journal of Crohn's and Colitis, 2020, 14, 267-273.	0.6	24
242	Review article: withdrawal of 5â€aminosalicylates in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 73-84.	1.9	24
243	A dietary intervention to improve the microbiome composition of pregnant women with Crohn's disease and their offspring: The MELODY (Modulating Early Life Microbiome through Dietary) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 100573.	0.5	24
244	Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immuneâ€mediated inflammatory diseases: A European retrospective observational study. United European Gastroenterology Journal, 2021, 9, 1136-1147.	1.6	24
245	Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. American Journal of Gastroenterology, 2020, 115, 1236-1245.	0.2	23
246	Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 116-125.e5.	2.4	23
247	Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients. Journal of Crohn's and Colitis, 2022, 16, 591-600.	0.6	23
248	Diffusion and perfusion MRI quantification in ileal Crohnâ€™s disease. European Radiology, 2019, 29, 993-1002.	2.3	22
249	Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis. Alimentary Pharmacology and Therapeutics, 2019, 50, 1189-1194.	1.9	22
250	Inflammatory bowel diseases among first-generation and second-generation immigrants in Denmark: a population-based cohort study. Gut, 2021, 70, 1037-1043.	6.1	22
251	The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry. Journal of Crohn's and Colitis, 2021, 15, 1877-1884.	0.6	22
252	Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic NaÃ¯ve Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 1579-1587.e2.	2.4	22

#	Article	IF	Citations
253	OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S612-S613.	0.6	21
254	Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 1095-1104.e9.	2.4	21
255	Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology, 2021, 161, 1156-1167.e3.	0.6	21
256	Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?. Gastroenterology, 2018, 154, 1201-1202.	0.6	20
257	Real-World Effectiveness and Safety of Tofacitinib in Crohnâ€™s Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clinical Gastroenterology and Hepatology, 2021, 19, 2207-2209.e3.	2.4	20
258	High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease Course. Inflammatory Bowel Diseases, 2023, 29, 423-429.	0.9	20
259	Stopping Mesalamine Therapy in Patients With Crohnâ€™s Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. Clinical Gastroenterology and Hepatology, 2020, 18, 1152-1160.e1.	2.4	19
260	Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry. American Journal of Gastroenterology, 2020, 115, 1923-1924.	0.2	19
261	Autoimmune pancreatitis and inflammatory bowel disease: Case series and review of the literature. Digestive and Liver Disease, 2016, 48, 893-898.	0.4	18
262	Disability in inflammatory bowel disease patients is associated with race, ethnicity and socioâ€economic factors. Alimentary Pharmacology and Therapeutics, 2019, 49, 564-571.	1.9	18
263	Predicting endoscopic remission in Crohnâ€™s disease by the modified multiplier SES-CD (MM-SES-CD). Gut, 2022, 71, 1078-1087.	6.1	18
264	Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohnâ€™s Disease. Gastroenterology, 2022, 163, 659-670.	0.6	18
265	Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohnâ€™s Disease Recurrence. Journal of Crohn's and Colitis, 2016, 11, jjw151.	0.6	17
266	Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohnâ€™s Disease: Results from the EXTEND Trial. Journal of Crohn's and Colitis, 2016, 11, jjw178.	0.6	17
267	Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. Journal of Crohn's and Colitis, 2018, 12, 1053-1066.	0.6	17
268	Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohnâ€™s Disease: A Systematic Review and Pooled Meta-analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 238-245.e4.	2.4	17
269	Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 403-405.	2.4	17
270	Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination Therapy. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 599-632.	2.3	17

#	Article	IF	Citations
271	IBDâ€"genes, bacteria and new therapeutic strategies. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 652-654.	8.2	16
272	Peroxisome proliferatorâ€activated receptor gamma (PPARÎ³) regulates lactase expression and activity in the gut. EMBO Molecular Medicine, 2017, 9, 1471-1481.	3.3	16
273	Efficient longâ€term depletion of CD20⁺ B cells by rituximab does not affect gutâ€resident plasma cells. Annals of the New York Academy of Sciences, 2018, 1415, 5-10.	1.8	16
274	Luminally polarized mural and vascular remodeling in ileal strictures of Crohn's disease. Human Pathology, 2018, 79, 42-49.	1.1	16
275	Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study. International Journal of Colorectal Disease, 2019, 34, 1771-1779.	1.0	16
276	Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 872-880.e1.	2.4	16
277	Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohnâ€™s Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. Journal of Crohn's and Colitis, 2021, 15, 462-470.	0.6	16
278	Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials. Journal of Crohn's and Colitis, 2021, 15, 1852-1863.	0.6	16
279	Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinibâ€"Implications for Cardiovascular Risk and Patient Management. Inflammatory Bowel Diseases, 2021, 27, 797-808.	0.9	15
280	Combination Therapy With Methotrexate in Inflammatory Bowel Disease: Time to COMMIT?. Gastroenterology, 2014, 146, 608-611.	0.6	14
281	Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis ofÂData From Clinical Trials. Clinical Gastroenterology and Hepatology, 2016, 14, 1753-1762.	2.4	14
282	Clinical updates on perianal fistulas in Crohnâ€™s disease. Expert Review of Gastroenterology and Hepatology, 2018, 12, 597-605.	1.4	14
283	Association Between Early-life Exposures and Inflammatory Bowel Diseases, Based on Analyses of Deciduous Teeth. Gastroenterology, 2020, 159, 383-385.	0.6	14
284	Vitamin C Deficiency in Inflammatory Bowel Disease: The Forgotten Micronutrient. Crohn's & Colitis 360, 2021, 3, otab009.	0.5	14
285	Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2022, 67, 1271-1277.	1.1	14
286	Molecular Characterization of Limited Ulcerative Colitis Reveals Novel Biology and Predictors of Disease Extension. Gastroenterology, 2021, 161, 1953-1968.e15.	0.6	14
287	Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2016, 10, 695-702.	0.6	13
288	P344 Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study. Journal of Crohn's and Colitis, 2019, 13, S274-S275.	0.6	13

#	Article	IF	Citations
289	Bariatric Surgery and Risk of New-onset Inflammatory Bowel Disease: A Nationwide Cohort Study. Journal of Crohn's and Colitis, 2021, 15, 1474-1480.	0.6	13
290	OP18 Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohnâ€™s Disease: Results from the phase 2 DIVERGENCE 2 study. Journal of Crohn's and Colitis, 2022, 16, i019-i021.	0.6	13
291	De-escalation of Therapy in Inflammatory Bowel Disease. Current Gastroenterology Reports, 2018, 20, 35.	1.1	12
292	OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohnâ€™s disease: long-term data from CALM. Journal of Crohn's and Colitis, 2019, 13, S024-S025.	0.6	12
293	Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data. Journal of Crohn's and Colitis, 2019, 13, 1257-1264.	0.6	12
294	Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 257-258.	2.4	12
295	IBD in the COVID-19 era: the value of international collaboration. The Lancet Gastroenterology and Hepatology, 2020, 5, 887-888.	3.7	12
296	Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series. Clinical Immunology, 2020, 212, 108362.	1.4	12
297	Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 1588-1597.e3.	2.4	12
298	Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open, 2021, 11, e049740.	0.8	12
299	Net Remission Rates with Biologic Treatment in Crohnâ€™s Disease: A Reappraisal of the Clinical Trial Data. Clinical Gastroenterology and Hepatology, 2023, 21, 1348-1350.	2.4	12
300	Polymorphisms in the Mannose-Binding Lectin Gene are Associated with Defective Mannose-Binding Lectin Functional Activity in Crohnâ€™s Disease Patients. Scientific Reports, 2016, 6, 29636.	1.6	11
301	Post-operative recurrence of Crohnâ€™s disease after definitive stoma: an underestimated risk. International Journal of Colorectal Disease, 2017, 32, 453-458.	1.0	11
302	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflammatory Bowel Diseases, 2019, 25, 1854-1861.	0.9	11
303	Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry. Journal of Crohn's and Colitis, 2021, 15, 860-863.	0.6	11
304	COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions. Gastroenterology, 2021, 160, 1447-1451.	0.6	11
305	Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [RemicadeÂ®] or Conventional Therapy. Journal of Crohn's and Colitis, 2019, 13, 1148-1157.	0.6	10
306	Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity. Gut, 2020, 69, 401-402.	6.1	10

#	Article	IF	Citations
307	Prevalence and Progression of Incidental Terminal Ileitis on Non-diagnostic Colonoscopy: A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis, 2021, 15, 1455-1463.	0.6	10
308	Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohnâ€™s Disease: A Post-hoc Analysis. Journal of Crohn's and Colitis, 2021, 15, 1649-1657.	0.6	10
309	Editorial: biologics in inflammatory bowel diseaseâ€•time for direct comparisons. Alimentary Pharmacology and Therapeutics, 2017, 46, 68-69.	1.9	9
310	The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. Inflammatory Bowel Diseases, 2019, 26, 643-652.	0.9	9
311	Evaluation of ileal Crohnâ€™s disease response to TNF antagonists: Validation of MR enterography for assessing response. Initial results. European Journal of Radiology Open, 2020, 7, 100217.	0.7	9
312	Age Is Just a Numberâ€"Frailty Associates With Outcomes of Patients With Inflammatory Bowel Disease. Gastroenterology, 2020, 158, 2041-2043.	0.6	9
313	New Gastrointestinal Symptoms Are Common in Inflammatory Bowel Disease Patients With COVID-19: Data From an International Registry. Inflammatory Bowel Diseases, 2021, , .	0.9	9
314	Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations. Inflammatory Bowel Diseases, 2022, 28, 649-651.	0.9	9
315	OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme. Journal of Crohn's and Colitis, 2022, 16, i036-i037.	0.6	9
316	Treatment With Biologic Agents Has Not Reduced SurgeriesÂAmong Patients With Crohnâ€™s Disease With ShortÂBowel Syndrome. Clinical Gastroenterology and Hepatology, 2017, 15, 1908-1914.e2.	2.4	8
317	Uric acid levels are independent of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohnâ€™s disease: A reappraisal of the role of S. cerevisiae in this setting. Virulence, 2018, 9, 1224-1229.	1.8	8
318	OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohnâ€™s disease: final results from the GEMINI LTS study. Journal of Crohn's and Colitis, 2019, 13, S018-S020.	0.6	8
319	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. Crohn's & Colitis 360, 2020, 2, otaa039.	0.5	8
320	Luminal Narrowing Alone Allows an Accurate Diagnosis of Crohnâ€™s Disease Small Bowel Strictures at Cross-Sectional Imaging. Journal of Crohn's and Colitis, 2021, 15, 1009-1018.	0.6	8
321	Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. Journal of Crohn's and Colitis, 2019, 13, 1227-1233.	0.6	7
322	Inflammatory Bowel Disease Clusters Within Affected Sibships in Ashkenazi Jewish Multiplex Families. Gastroenterology, 2020, 159, 381-382.	0.6	7
323	Cost-effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 1169-1176.	0.9	7
324	Is Prevention the Best Way to Modify Inflammatory Bowel Disease? How Close Are We?. Gastroenterology, 2022, 162, 1452-1455.	0.6	7

#	Article	IF	Citations
325	The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis. Inflammatory Bowel Diseases, 2022, , .	0.9	7
326	A United States expert consensus to standardise definitions, followâ€up, and treatment targets for extraâ€intestinal manifestations in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1179-1191.	1.9	7
327	Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials. Inflammatory Bowel Diseases, 2023, 29, 1-8.	0.9	7
328	Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. Dermatology and Therapy, 2022, 12, 1431-1446.	1.4	7
329	IBD Therapy: New Targets and Unmet Needs. Nestle Nutrition Institute Workshop Series, 2014, 79, 153-160.	1.5	6
330	Anti-TNF Withdrawal in Inflammatory Bowel Disease. GE Portuguese Journal of Gastroenterology, 2016, 23, 153-161.	0.3	6
331	Mortality and Rates of Graft Rejection or Failure Following Intestinal Transplantation in Patients With vs Without Crohnâ€™sÂDisease. Clinical Gastroenterology and Hepatology, 2016, 14, 1574-1581.	2.4	6
332	Evidence for Life Before Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 825-828.	2.4	6
333	Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. Inflammatory Bowel Diseases, 2019, 25, 163-171.	0.9	6
334	What Are the Most Challenging Aspects of Inflammatory Bowel Disease? An International Survey of Gastroenterologists Comparing Developed and Developing Countries. Inflammatory Intestinal Diseases, 2021, 6, 78-86.	0.8	6
335	P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications. Journal of Crohn's and Colitis, 2022, 16, i514-i514.	0.6	6
336	Categorising Endoscopic Severity of Crohnâ€™s Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. Journal of Crohn's and Colitis, 2022, 16, 1011-1019.	0.6	6
337	Outcomes of COVID-19 Infections in Vaccinated Patients with Inflammatory Bowel Disease: Data From an International Registry. Inflammatory Bowel Diseases, 2022, 28, 1126-1129.	0.9	5
338	Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. Inflammatory Bowel Diseases, 2022, 28, 1555-1564.	0.9	5
339	P729 The SAPPHIRE registry: Safety of immunosuppression in a prospective cohort of inflammatory bowel disease patients with a HIstoRy of CancEr. Journal of Crohn's and Colitis, 2020, 14, S585-S587.	0.6	4
340	Therapeutic Drug Monitoring of Anti-tumour Necrosis Factor Agents in Inflammatory Bowel Diseases: The Jury Is Still Out. Journal of Crohn's and Colitis, 2020, 14, 1035-1036.	0.6	4
341	A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. American Journal of Gastroenterology, 2021, 116, 1709-1719.	0.2	4
342	Noninfectious Pulmonary Complications Associated With Anti-Integrin Therapy: A Case Report and Systematic Review of the Literature. Inflammatory Bowel Diseases, 2022, 28, 479-483.	0.9	4

#	Article	IF	Citations
343	COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States. Clinical Gastroenterology and Hepatology, 2021, 19, 2210-2213.e3.	2.4	4
344	DOP39 Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programme. Journal of Crohn's and Colitis, 2022, 16, i088-i089.	0.6	4
345	DOP44 Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, i093-i094.	0.6	4
346	Impact of thiopurine discontinuation at antiâ€tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study. Alimentary Pharmacology and Therapeutics, 2022, 55, 1128-1138.	1.9	4
347	Breastfeeding Is Associated with Lower Likelihood of Helicobacter Pylori Colonization in Babies, Based on a Prospective USA Maternal-Infant Cohort. Digestive Diseases and Sciences, 2022, , 1.	1.1	4
348	Measuring patients’ satisfaction with their anti-TNF treatment in severe Crohn’s disease: scoring and psychometric validation of the Satisfaction for PAtients in Crohn’s diseasE Questionnaire (SPACE-Q©). Patient Preference and Adherence, 2014, 8, 1671.	0.8	3
349	Comment on â€˜Anti-Adhesion Therapies and the Rule of 3 for Rare Eventsâ€™. American Journal of Gastroenterology, 2014, 109, 1083-1084.	0.2	3
350	The Crohnâ€™s Diseaseâ€“Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clinical Gastroenterology and Hepatology, 2016, 14, e121-e122.	2.4	3
351	Need for Caution in Diagnosis of Irritable Bowel Syndrome in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 1315.	2.4	3
352	Identification of volumetric laser endomicroscopy features of colon polyps with histologic correlation. Gastrointestinal Endoscopy, 2018, 87, 1558-1564.	0.5	3
353	Microbial-Host Interactions in Inflammatory Bowel Disease, Functional Bowel Disease, Obesity and Obesity-Related Metabolic Disease. Gastroenterology, 2018, 155, 1283-1286.	0.6	3
354	P160 Faecal Lactoferrin is a reliable IBD biomarker during pregnancy. Journal of Crohn's and Colitis, 2018, 12, S178-S178.	0.6	3
355	Inflammatory Bowel Disease Therapy and Venous Thromboembolism. Current Treatment Options in Gastroenterology, 2020, 18, 462-475.	0.3	3
356	Impact of COVID-19 on Healthcare Resource Utilisation Among Patients with Inflammatory Bowel Disease in the USA. Journal of Crohn's and Colitis, 2022, 16, 1405-1414.	0.6	3
357	Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease. Gut, 2022, 71, 1919.2-1922.	6.1	3
358	An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Expert Opinion on Pharmacotherapy, 2022, 23, 893-904.	0.9	3
359	105 Natural History of Ulcerative Colitis in the Elderly: A Population-Based Study. Gastroenterology, 2012, 142, S-25.	0.6	2
360	DOP037 Long-term outcome of paediatric-onset ulcerative colitis: early years are shaping the future. Journal of Crohn's and Colitis, 2014, 8, S32-S33.	0.6	2

#	Article	IF	Citations
361	Management of Severe Ulcerative Colitis. Current Treatment Options in Gastroenterology, 2015, 13, 59-76.	0.3	2
362	OP019 Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301). Journal of Crohn's and Colitis, 2017, 11, S11-S12.	0.6	2
363	Clinical disease activity in the CALM study â€“ Authors' reply. Lancet, The, 2018, 391, 1482.	6.3	2
364	Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with antiâ€<scp>TNF</scp> medications. Alimentary Pharmacology and Therapeutics, 2018, 47, 446-447.	1.9	2
365	A147 RESPONSE AND REMISSION AFTER 16 WEEKS OF USTEKINUMABâ€“ AN ALL PATIENTS ANALYSIS FROM THE UNITI CROHNâ€™S STUDIES. Journal of the Canadian Association of Gastroenterology, 2018, 1, 219-220.	0.1	2
366	A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATEâ€“SEVERE CROHNâ€™S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY. Journal of the Canadian Association of Gastroenterology, 2018, 1, 147-148.	0.1	2
367	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 785.	2.4	2
368	Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 997-998.	1.9	2
369	The Chicago Classification of Pouchitis: An Important Step Toward a Needed Consensus. Clinical Gastroenterology and Hepatology, 2022, 20, 281-282.	2.4	2
370	Diagnostic accuracy of patientâ€reported outcomes in predicting endoscopic subscore in patients with ulcerative colitis. GastroHep, 2021, 3, 161-168.	0.3	2
371	P271 Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY Study. Journal of Crohn's and Colitis, 2021, 15, S305-S305.	0.6	2
372	Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug?. Current Pharmaceutical Design, 2019, 25, 57-63.	0.9	2
373	Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2022, 16, 616-624.	0.6	2
374	A Review of the Totality of Evidence for the Development and Approval of ABPÂ710 (AVSOLA), an Infliximab Biosimilar. Advances in Therapy, 2022, 39, 44-57.	1.3	2
375	P031â€ƒImpact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study. American Journal of Gastroenterology, 2021, 116, S8-S8.	0.2	2
376	Response to Cote-Daigneaut et al.. American Journal of Gastroenterology, 2016, 111, 1851-1852.	0.2	1
377	DOP019 Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohnâ€™s disease: aÂGEMINI 2 post hoc analysis. Journal of Crohn's and Colitis, 2017, 11, S36-S38.	0.6	1
378	OP009 A combination of clinical, serological, and genetic factors predicts complicated disease course in paediatric-onset Crohnâ€™s disease: results from a population-based study. Journal of Crohn's and Colitis, 2018, 12, S007-S007.	0.6	1

#	Article	IF	Citations
379	Neonatal Life Events and the Risk of Inflammatory Bowel Disease. Gastroenterology, 2019, 157, 1440-1441.	0.6	1
380	P376 Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohnâ€™s disease: results from the Phase 3b VERSIFY trial. Journal of Crohn's and Colitis, 2019, 13, S293-S294.	0.6	1
381	P360 Inflammatory microheterogeneity in ulcerative colitis: implications for microscopic assessment of disease activity. Journal of Crohn's and Colitis, 2019, 13, S284-S285.	0.6	1
382	New Blood Marker of Endoscopic Disease Activityâ€"A Step Forward in Treating Crohnâ€™s Disease to Target?. Gastroenterology, 2020, 158, 463-465.	0.6	1
383	P508 Safety and efficacy of combining biological therapies together or with small molecules in patients with inflammatory bowel disease: A retrospective multicentre national observational case series study. Journal of Crohn's and Colitis, 2020, 14, S440-S442.	0.6	1
384	P144 Vitamin C deficiency in inflammatory bowel disease: the forgotten micronutrient. Journal of Crohn's and Colitis, 2020, 14, S209-S209.	0.6	1
385	P030 Dynamics of intestinal inflammation and microbial dysbiosis in pregnant women with IBD and their infants. Journal of Crohn's and Colitis, 2020, 14, S146-S147.	0.6	1
386	Reply. Gastroenterology, 2021, 160, 1886-1887.	0.6	1
387	DOP58 Non-white race is associated with decreased efficacy of tumor necrosis factor antagonist therapy in Ulcerative Colitis: A post-hoc analysis of individual level data from golimumab clinical trials. Journal of Crohn's and Colitis, 2021, 15, S093-S094.	0.6	1
388	Risk of Postpartum Flare Hospitalizations in Patients with Inflammatory Bowel Disease Persists After Six Months. Digestive Diseases and Sciences, 2021, , 1.	1.1	1
389	OP06 5-aminosalicylates are not associated with adverse outcomes in Inflammatory Bowel Disease patients with COVID-19: Analysis from an international registry. Journal of Crohn's and Colitis, 2021, 15, S006-S007.	0.6	1
390	P433 Sex-based differences in response to tumor necrosis factor inhibitor induction therapy for ulcerative colitis: a pooled analysis of individual patient-level clinical trials data. Journal of Crohn's and Colitis, 2021, 15, S435-S436.	0.6	1
391	P117 point-of-care intestinal ultrasound for the detection of postoperative Crohnâ€™s disease endoscopic recurrence. Journal of Crohn's and Colitis, 2022, 16, i208-i208.	0.6	1
392	P486 Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials. Journal of Crohn's and Colitis, 2022, 16, i452-i452.	0.6	1
393	DOP82 Achievement of steroid-free remission in patients with moderately to severely active Crohnâ€™s Disease during treatment with risankizumab. Journal of Crohn's and Colitis, 2022, 16, i125-i126.	0.6	1
394	P653 The changing epidemiology of IBD in the western world: a population-based study from Denmark. Journal of Crohn's and Colitis, 2022, 16, i566-i567.	0.6	1
395	Baseline C-reactive protein is associated with disease progression in patients with CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2011, 17, S22.	0.9	0
396	Reply. Gastroenterology, 2014, 146, 868-869.	0.6	0

#	Article	IF	Citations
397	Editorial: post hoc analysis of <scp>SONIC</scp> trial â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2015, 41, 1211-1211.	1.9	0
398	P-017â€ƒYlâ€ƒMucosal Healing Is Associated with Improved Long-Term Outcomes in Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, S14.	0.9	0
399	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 483.	2.4	0
400	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 1361-1362.	2.4	0
401	Letter: mucosal healing is associated with improved longâ€term outcomes in Crohn's disease â€“ authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 1347-1348.	1.9	0
402	Editorial: serologic microbial associated markers to predict Crohn's disease behaviour â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 301-302.	1.9	0
403	Reply. Gastroenterology, 2016, 150, 1039.	0.6	0
404	P-016â€ƒYlâ€ƒMucosal Healing Is Associated with Improved Long-Term Outcomes in CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2016, 22, S14.	0.9	0
405	P121 Antimicrobial antibodies and inflammatory markers are present in the serum of patients with IBD years before diagnosis and can predict disease. Journal of Crohn's and Colitis, 2017, 11, S136-S137.	0.6	0
406	P734 The sex ratio of inflammatory bowel disease varies according to age at onset: results from a worldwide survey. Journal of Crohn's and Colitis, 2017, 11, S456-S457.	0.6	0
407	Agreement Between Crohnâ€™s Disease Endoscopic Severity Scores Derived from Live, Video-recorded, and Central Readings. Inflammatory Bowel Diseases, 2018, 24, e6-e7.	0.9	0
408	A102 TOLERABILITY OF USTEKINUMAB IN INDUCTION AND MAINTENANCE FOR THE TREATMENT OF CROHNâ€™S DISEASE. Journal of the Canadian Association of Gastroenterology, 2018, 1, 153-154.	0.1	0
409	Editorial: de novo inflammatory bowel disease following bariatric surgeryâ€”potential implications for research and clinical practice. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1540-1540.	1.9	0
410	P413 A simple scoring tool predicts exposureâ€“response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohnâ€™s disease. Journal of Crohn's and Colitis, 2019, 13, S316-S316.	0.6	0
411	DOP35 Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohnâ€™s disease, is significantly amplified in patients with a complicated phenotype. Journal of Crohn's and Colitis, 2019, 13, S045-S046.	0.6	0
412	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 796-797.	2.4	0
413	P314 Long-term fate of the excluded rectum in Crohnâ€™s disease. Journal of Crohn's and Colitis, 2019, 13, S257-S258.	0.6	0
414	P404 Stopping 5-aminosalicylates in Crohnâ€™s disease patients starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Journal of Crohn's and Colitis, 2019, 13, S310-S311.	0.6	0

#	Article	IF	Citations
415	P407 Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study. Journal of Crohn's and Colitis, 2019, 13, S312-S313.	0.6	0
416	P631 Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S433-S433.	0.6	0
417	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 573-574.	2.4	0
418	P092 Pathogenic B-cell response in ulcerative colitis that associates with treatment resistance and disease complications. Journal of Crohn's and Colitis, 2020, 14, S181-S182.	0.6	0
419	P457 IBD couples and their offspring: a European survey. Journal of Crohn's and Colitis, 2020, 14, S407-S408.	0.6	0
420	P546 Ileal ulcer size significantly impacts the ability to achieve endoscopic remission: a post-hoc analysis from the SONIC trial. Journal of Crohn's and Colitis, 2020, 14, S465-S465.	0.6	0
421	P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohnâ€™s disease: Data from the CALM study. Journal of Crohn's and Colitis, 2020, 14, S264-S266.	0.6	0
422	DOP42 Impact of discontinuing thiopurines at anti-TNF initiation in inflammatory bowel disease: A nationwide Danish cohort study. Journal of Crohn's and Colitis, 2020, 14, S079-S080.	0.6	0
423	DOP15 Transmural healing with vedolizumab in patients with active Crohnâ€™s disease. Journal of Crohn's and Colitis, 2020, 14, S053-S056.	0.6	0
424	Reply. Gastroenterology, 2021, 160, 476-477.	0.6	0
425	Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab. Inflammatory Bowel Diseases, 2021, 27, 1963-1967.	0.9	0
426	Reply. Clinical Gastroenterology and Hepatology, 2022, 20, 469.	2.4	0
427	DOP03 Early change in epithelial neutrophilic infiltrate predicts long-term response to biologics in Ulcerative Colitis. Journal of Crohn's and Colitis, 2021, 15, S042-S043.	0.6	0
428	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
429	Baseline Histological Findings Do Not Predict the Risk of Subsequent Extension in Patients with Limited Ulcerative Colitis. Digestive Diseases and Sciences, 2021, , 1.	1.1	0
430	P065 Conservation of breast milk cytokine profiles in consecutive pregnancies of women with inflammatory bowel disease. Journal of Crohn's and Colitis, 2021, 15, S170-S171.	0.6	0
431	P048 Intestinal inflammation and microbiome diversity are conserved more in consecutive pregnancies among women with inflammatory bowel disease compared to healthy controls. Journal of Crohn's and Colitis, 2021, 15, S156-S158.	0.6	0
432	P326 An exploratory analysis of the impact of COVID-19 on colonoscopy procedures and new biologic treatment initiation among patients with Inflammatory Bowel Disease in the United States. Journal of Crohn's and Colitis, 2021, 15, S350-S351.	0.6	0

#	Article	IF	Citations
433	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 1301-1302.	2.4	0
434	Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis. Digestive Diseases and Sciences, 2021, , 1.	1.1	0
435	Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
436	Conjugal inflammatory bowel disease: a systematic review and European survey. Annals of Gastroenterology, 2021, 34, 361-369.	0.4	0
437	Chemotherapy tolerance and oncologic outcomes in colorectal cancer (CRC) patients with and without inflammatory bowel disease (IBD).. Journal of Clinical Oncology, 2016, 34, e15162-e15162.	0.8	0
438	P655 Early life mebendazole exposure increases the risk of adult-onset ulcerative colitis: a population-based cohort study. Journal of Crohn's and Colitis, 2022, 16, i567-i568.	0.6	0
439	DOP59 Development of a novel Ulcerative Colitis (UC) endoscopic activity prediction model using machine learning (ML). Journal of Crohn's and Colitis, 2022, 16, i105-i106.	0.6	0
440	P663 Mild COVID-19 disease and breakthrough cases among children with inflammatory bowel disease: An update from an international registry. Journal of Crohn's and Colitis, 2022, 16, i572-i573.	0.6	0
441	P050 A comparison of the Gut Microbiota in Pregnant Women with and without Inflammatory Bowel Disease and Their Offspring in Hong Kong and United States. Journal of Crohn's and Colitis, 2022, 16, i163-i163.	0.6	0
442	DOP16 Categorizing endoscopic severity of Crohnâ€™s Disease using the Modified Multiplier SES-CD (MM-SES-CD). Journal of Crohn's and Colitis, 2022, 16, i065-i066.	0.6	0
443	P342 Trans-continental analysis of over, 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium. Journal of Crohn's and Colitis, 2022, 16, i357-i358.	0.6	0
444	Treat to target with ustekinumab for Crohn's disease. The Lancet Gastroenterology and Hepatology, 2022, , .	3.7	0
445	Letter: rationalising aminosalicylates in inflammatory bowel diseaseâ€”authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1621-1621.	1.9	0
446	Long-Term Outcomes of the Excluded Rectum in Crohnâ€™s Disease: A Multicenter International Study. Inflammatory Bowel Diseases, 2022, , .	0.9	0
447	CD: Induction treatment with upadacitinib successful in clinical and endoscopic ratings. , 0, , .		0